US 12,171,787 B2
Methods and compositions for modulating angiogenesis and vasculogenesis
Monique Dao, Huntington Beach, CA (US); Ciara Tate, Chicago, IL (US); and Casey C. Case, San Mateo, CA (US)
Assigned to SanBio, Inc., Oakland, CA (US)
Filed by SanBio, Inc., Mountain View, CA (US)
Filed on Mar. 14, 2022, as Appl. No. 17/654,778.
Application 17/654,778 is a continuation of application No. 16/269,000, filed on Feb. 6, 2019, granted, now 11,304,982.
Application 16/269,000 is a continuation of application No. 15/608,656, filed on May 30, 2017, granted, now 10,245,286, issued on Apr. 2, 2019.
Application 15/608,656 is a continuation of application No. 15/063,290, filed on Mar. 7, 2016, abandoned.
Application 15/063,290 is a continuation of application No. 13/750,772, filed on Jan. 25, 2013, abandoned.
Claims priority of provisional application 61/709,619, filed on Oct. 4, 2012.
Claims priority of provisional application 61/637,740, filed on Apr. 24, 2012.
Claims priority of provisional application 61/591,486, filed on Jan. 27, 2012.
Prior Publication US 2022/0193144 A1, Jun. 23, 2022
Int. Cl. A61K 35/28 (2015.01); A61K 35/34 (2015.01); A61K 35/44 (2015.01); A61K 38/18 (2006.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); A61L 27/38 (2006.01); A61P 9/10 (2006.01); C12N 5/071 (2010.01); C12N 5/0775 (2010.01)
CPC A61K 35/34 (2013.01) [A61K 35/28 (2013.01); A61K 35/44 (2013.01); A61K 38/1866 (2013.01); A61K 45/06 (2013.01); A61L 27/3834 (2013.01); A61P 9/10 (2018.01); C12N 5/0662 (2013.01); C12N 5/0663 (2013.01); C12N 5/0668 (2013.01); C12N 5/0697 (2013.01); A61K 48/00 (2013.01); C12N 2501/42 (2013.01); C12N 2502/1347 (2013.01); C12N 2502/28 (2013.01); C12N 2510/02 (2013.01); C12N 2533/90 (2013.01)] 10 Claims
 
1. A method for augmenting angiogenesis in a subject that does not have an ischemic disorder, the method comprising:
implanting a population of cells into the subject, wherein the cell population is made by a method comprising:
(a) contacting a culture of mesenchymal stem cells with a polynucleotide comprising sequences encoding a Notch intracellular domain (NICD) wherein said polynucleotide does not encode a full-length Notch protein,
(b) selecting cells that comprise the polynucleotide of step (a), and
(c) further culturing the selected cells of step (b) in the absence of selection and in the absence of trophic factors;
wherein the cell population produces higher levels of angiogenin, angiopoietin-2 (ANG-2) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) than does a mesenchymal stem cell population containing the same number of cells.